VERTEX PHARMACEUTICALS INC MA
For the period ended Sep 30, 2024. Filed Nov 5, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2024 · Filed Nov 5, 2024
VRTX$547.89-0.5%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Cash Flows -
| Nine Months Ended September 30, | ||
|---|---|---|
| 2024 | 2023 | |
| Cash flows from operating activities: | ||
| Net (loss) income | $(1,448.6) | $2,650.8 |
| Adjustments to reconcile net (loss) income to net cash (used in) provided by operating activities: | ||
| Stock-based compensation expense | 530.7 | 372.6 |
| Depreciation and amortization expense | 160.7 | 122.3 |
| Deferred income taxes | (400.4) | (405.5) |
| Loss on equity securities | 50.5 | 0.2 |
| Increase (decrease) in fair value of contingent consideration | 0.7 | (1.3) |
| Other non-cash items, net | (16.2) | (9.6) |
| Changes in operating assets and liabilities: | ||
| Accounts receivable, net | (168.3) | (99.5) |
| Inventories | (369.8) | (252.9) |
| Prepaid expenses and other assets | (35.7) | (94.4) |
| Accounts payable | 41.1 | 80.5 |
| Accrued expenses | 533.0 | 786.1 |
| Other liabilities | 45.1 | 153.4 |
| Net cash (used in) provided by operating activities | (1,077.2) | 3,302.7 |
| Cash flows from investing activities: | ||
| Purchases of available-for-sale debt securities | (5,279.6) | (2,798.0) |
| Sales and maturities of available-for-sale debt securities | 3,005.4 | 621.0 |
| Acquisition of available-for-sale debt securities from Alpine Immune Sciences, Inc. | (258.0) | — |
| Purchases of property and equipment | (205.1) | (142.3) |
| Net payments related to finite-lived intangible assets | (187.7) | — |
| Sale of equity securities | — | 95.1 |
| Other investing activities | (23.1) | (31.0) |
| Net cash used in investing activities | (2,948.1) | (2,255.2) |
| Cash flows from financing activities: | ||
| Issuances of common stock under benefit plans | 80.3 | 88.2 |
| Repurchases of common stock | (759.2) | (278.1) |
| Payments in connection with common stock withheld for employee tax obligations | (397.7) | (222.9) |
| Payments on finance leases | (32.3) | (32.9) |
| Other financing activities | 5.3 | 3.3 |
| Net cash used in financing activities | (1,103.6) | (442.4) |
| Effect of changes in exchange rates on cash | 4.7 | (0.5) |
| Net (decrease) increase in cash, cash equivalents and restricted cash | (5,124.2) | 604.6 |
| Cash, cash equivalents and restricted cash—beginning of period | 10,372.3 | 10,512.0 |
| Cash, cash equivalents and restricted cash—end of period | $5,248.1 | $11,116.6 |
| Supplemental disclosure of cash flow information: | ||
| Cash paid for income taxes | $810.3 | $919.1 |
| Cash paid for interest | $27.8 | $32.6 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.